Cited by 386Cancer, Hypoxia, and MetabolismErythropoietin and Anemia TreatmentUbiquitin and proteasome pathways

Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-α-prolyl-4-hydroxylases

Open access
MARXSEN, Jan H., STENGEL, Petra, DOEGE, Kathrin, HEIKKINEN, Pekka, JOKILEHTO, Terhi, WAGNER, Thomas, JELKMANN, Wolfgang, JAAKKOLA, Panu +1 more·2004·Biochemical Journal

Abstract

An important regulator involved in oxygen-dependent gene expression is the transcription factor HIF (hypoxia-inducible factor), which is composed of an oxygen-sensitive α-subunit (HIF-1α or HIF-2α) and a constitutively expressed β-subunit. In normoxia, HIF-1α is destabilized by post-translational hydroxylation of Pro-564 and Pro-402 by a family of oxygen-sensitive dioxygenases. The three HIF-modifying human enzymes have been termed prolyl hydroxylase domain containing proteins (PHD1, PHD2 and PHD3). Prolyl hydroxylation leads to pVHL (von-Hippel-Lindau protein)-dependent ubiquitination and rapid proteasomal degradation of HIF-1α. In the present study, we report that human PHD2 and PHD3 are induced by hypoxia in primary and transformed cell lines. In the human osteosarcoma cell line, U2OS, selective suppression of HIF-1α expression by RNA interference resulted in a complete loss of hypoxic induction of PHD2 and PHD3. Induction of PHD2 by hypoxia was lost in pVHL-deficient RCC4 cells. These results suggest that hypoxic induction of PHD2 and PHD3 is critically dependent on HIF-α. Using a VHL capture assay, we demonstrate that HIF-α prolyl-4-hydroxylase capacity of cytoplasmic and nuclear protein extracts was enhanced by prolonged exposure to hypoxia. Degradation of HIF-1α after reoxygenation was accelerated, which demonstrates functional relevance of the present results. We propose a direct, negative regulatory mechanism, which limits accumulation of HIF-1α in hypoxia and leads to accelerated degradation on reoxygenation after long-term hypoxia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1042/bj20040620

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 36 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
MARXSEN, J. H., STENGEL, P., DOEGE, K., HEIKKINEN, P., JOKILEHTO, T., WAGNER, T., JELKMANN, W., JAAKKOLA, P., & METZEN, E.
Affiliations
  • University of Lübeck (DE)
  • Åbo Akademi University (FI)
Corresponding author
WAGNER, Thomas
Venue
Biochemical Journal
Published
2004-07-27
Volume
381
Issue
3
Pages
761-767
ISSN
  • 0264-6021 (ISSN-L)
  • 1470-8728
OpenAlex
W2062805420
Cited by
386
References
36
Citations by year
2026: 14 · 2025: 26 · 2024: 26 · 2023: 17 · 2022: 15 · 2021: 20 · 2020: 10 · 2019: 13 · 2018: 12 · 2017: 18 · 2016: 12 · 2015: 20 · 2014: 16 · 2013: 17 · 2012: 12
FWCI
8.97
Type
journal article
Language
en
Open access
Locations
  • Biochemical Journal (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Deutsche Forschungsgemeinschaft (SFB367)
  • Academy of Finland
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords
HIF-1, HIF-1α, prolyl 4-hydroxylase, PHD2, PHD3, HIF-1α degradation, hypoxia, von Hippel-Lindau protein, ubiquitination, proteasomal degradation, reoxygenation, oxygen sensing, transcriptional regulation, osteosarcoma cells, RNA interference
MeSH terms
Hypoxia, Bone Neoplasms, Cell Line, DNA-Binding Proteins, Enzyme Induction, Epithelial Cells, Half-Life, Carcinoma, Hepatocellular, Humans, Hydroxylation, Kidney Neoplasms, Kidney Tubules, Proximal, Liver Neoplasms, Nuclear Proteins, Oxygen, Procollagen-Proline Dioxygenase, RNA, Messenger, Osteosarcoma, Transcription Factors, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Immediate-Early Proteins, Adenocarcinoma, Clear Cell, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Cell Line, Tumor, Dioxygenases, Hypoxia-Inducible Factor 1, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit, Hypoxia-Inducible Factor-Proline Dioxygenases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review